Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep40: Inhibitory actions of vitamin K
Article first published online: 4 FEB 2005
Copyright © 1995 Wiley-Liss, Inc.
Journal of Cellular Physiology
Volume 165, Issue 3, pages 459–467, December 1995
How to Cite
Bouzahzah, B., Nishikawa, Y., Simon, D. and Carr, B. I. (1995), Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep40: Inhibitory actions of vitamin K. J. Cell. Physiol., 165: 459–467. doi: 10.1002/jcp.1041650303
- Issue published online: 4 FEB 2005
- Article first published online: 4 FEB 2005
- Manuscript Accepted: 26 APR 1995
- Manuscript Received: 1 APR 1994
The growth characteristics of a newly established cell line, Hep40, derived from a human hepatoma are described. An absolute requirement was found for serum to mediate cell growth. Neither EGF, TGF-α, nor HGF altered cell growth in the presence or absence of serum. A partial suppression of cell growth was achieved by several TGF-β family proteins. Affinity crosslinking gels using 125I-labeled TGF-β showed a significant decrease in the TGF-β cell-surface type II receptor in Hep40 cells, compared to the TGF-β-sensitive Hep3B cell line. However, growth could be completely suppressed by addition of vitamins K to the culture medium in both Hep40 and several other hepatoma cell lines. Growth suppression by vitamins K was accompanied by an increased level of transcripts for c-myc, c-jun, and prothrombin genes, in contrast to the actions of TGF-β1 protein, which caused a decrease in the level of c-myc transcripts. These data show that this new human hepatoma cell line has partial resistance to growth inhibition by TGF-β with a unique TGF-β receptor defect. However, growth was completely suppressed by vitamins K. The differing gene expression patterns in response to TGF-β as compared to vitamin K suggest that these two growth inhibitors act through differing pathways. © 1995 Wiley-Liss Inc.